Fexofenadine HCI

This page contains recent news articles, when available, and an overview of Fexofenadine HCI but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

United States top 250 generic drugs by retail sales and manufacturer...  -  Apr 23, 2007
Clopidogrel bisulfate $375133824.78 Prasco Labs Fexofenadine HCI $343789356.17 Roxane ... Fluticasone propionate $294299784.23 Teva USA Fexofenadine HCI ... $20.00 - Chain Drug Review - Alacra Store

Global top 300 multisource generic pharmaceuticals by sales, …  -  Apr 28, 2008
Endocet 60951071270 31 Dr. Reddy's Labs Fexofenadine HCI 55111019401 32 Greenstone ... Morphine sulfate 60951065870 244 Prasco Labs Fexofenadine HCI ... $20.00 - Chain Drug Review - Alacra Store

Top 300 multisource generics by manufacturer and NDC11 number.(RX/ …  -  Apr 28, 2008
Morphine sulfate 60951065870 244Prasco Labs Fexofenadine HCI 66993010702 245Ranbaxy Amox Tr-potassium 63304050901 clavulanate 246Ivax Pharm. ... Pay-Per-View - Chain Drug Review - HighBeam Research

Barr Granted Summary Judgment on Additional Patent in Allegra(R) …  -  Apr 1, 2005
Barr filed an Abbreviated New Drug Application (ANDA) for Fexofenadine HCI 60 mg capsules in May 2001, an ANDA for Fexofenadine HCI 30 mg, 60 mg, ... $4.95 - PR Newswire - ECNext

Article: Top 250 multisource generics.(RX/GENERIC DRUGS)(Statistical ...  -  Apr 23, 2007
Clopidogrel bisulfate$375133824.78 Prasco Labs Fexofenadine HCI $343789356.17 ... Fluticasone propionate $294299784.23 Teva USA Fexofenadine HCI ... Pay-Per-View - Chain Drug Review - HighBeam Research

Press Release: Barr Granted Summary Judgment on Additional Patent in ...  -  Apr 1, 2005
Barr filed an Abbreviated New Drug Application (ANDA) for Fexofenadine HCI 60 mg capsules in May 2001, an ANDA for Fexofenadine HCI 30 mg, 60 mg, ... Pay-Per-View - PR Newswire - HighBeam Research

Prasco to market generic Allegra  -  Sep 14, 2005
Fexofenadine HCI is the most recent product from Prasco in its authorized generics program, which market brand company products under the Prasco label. Cincinnati Business Courier

Article: Antidote.(NEWS) - Medical Marketing & Media | HighBeam …  -  Jul 1, 2006
Medical Marketing & Media; April 1, 2000 ; 586 words ... ... form of Allegra (fexofenadine HCI) -- 180 mg tablets. The company also has submitted a new drug ... Pay-Per-View - Medical Marketing & Media - HighBeam Research

Concerta 72 mg, Allegra-D 24 hour.(New & Approved)  -  Jan 1, 2005
...(fexofenadine HCI 180 mg; pseudoephedrine HCl 240 mg, Aventis Pharmaceuticals Inc.) Allegra-D 24 Hour Extended-Release tablets are FDA approved for relief ... Free with registration - Family Practice News - AccessMyLibrary.com

The FDA.(Update) | Article from Medical Marketing & Media | HighBeam ...  -  Jun 1, 2007
The FDA approved Aventis Pharmaceuticals' new dosage form of Allegra (fexofenadine HCI) -- 180 mg tablets. The company also has submitted a new drug ... Pay-Per-View - Medical Marketing & Media - HighBeam Research

Prasco and sanofi-aventis Sign a Distribution and Supply Agreement...  -  Sep 12, 2005
Fexofenadine HCI is the latest product from Prasco in its Authorized Generics program bringing consumers brand quality, generic priced pharmaceuticals. ... $4.95 - Business Wire - ECNext

The Sanofi-Aventis Group.(extends research pact with Aventis …  -  Oct 1, 2005
The FDA approved Aventis Pharmaceuticals' new dosage form of Allegra (fexofenadine HCI) -- 180 mg tablets. The company also has submitted a new drug ... Pay-Per-View - Medical Marketing & Media - HighBeam Research

Getting allergic rhinitis under control: Part 2: long-term combination...  -  May 1, 2005
The efficacy and safety of fexofenadine HCI and pseudoephedrine, alone and in combination, in seasonal allergic rhinitis. J Allergy Clin Immunol. ... $4.95 - Journal of Respiratory Diseases - ECNext





Health Home | Conditions | Cancer | Medications | Surgery | Vaccines


The Cancer News Network


Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on cancernewsnetwork.org lead to other sites. cancernewsnetwork.org does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is CancerNewsNetwork.org responsible for dead or misdirected links.

IF YOU NEED A LINK OR TEXT REMOVED FROM THIS PAGE PLEASE CONTACT cancernewsnetwork (at) live.com.
We will do our best to accommodate your request.



COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy